1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Real-time Estimate Cboe Europe  -  07:25 2022-07-07 am EDT
11092.00 GBX   +1.04%
07:25aASTRAZENECA : Jefferies reiterates its Neutral rating
03:45aASTRAZENECA : JP Morgan reiterates its Buy rating
07/06China allows AstraZeneca's COVID preventive drug in southern city
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Trial Scheduled For April 2024 In BMS Patent Case Against AstraZeneca Regarding Anti-PDL1 Antibodies

05/24/2022 | 02:12am EDT

The District of Delaware has issued a scheduling order, setting a trial for April 2024, in Bristol Myers Squibb's (BMS) patent case against AstraZeneca. BMS filed its complaint against AstraZeneca on March 17, 2022, alleging infringement of eight patents related to anti-PD-L1 antibodies. According to BMS, the case "relates to groundbreaking treatments for cancer" using anti-PD-L1 antibodies that bind to PD-L1 (programmed death ligand 1) and serve as "checkpoint inhibitors that release the brakes on the immune systems, freeing the immune cells to recognize, attack and destroy cancer cells." The asserted patents include claims generally directed to monoclonal antibodies that cross-compete with a specific reference antibody for binding to human PD-L1, and methods of treating various cancers by administering an anti-PD-L1 antibody.

BMS contends that AstraZeneca's IMFINZI (durvalumab) is a PD-L1 blocking antibody that infringes the asserted patents. The FDA approved IMFINZI in 2017 for patients with certain types of urothelial carcinoma, and has since approved additional treatment indications.

The case is assigned to Visiting Judge Matthew F. Kennelly from the U.S. District Court for the Northern District of Illinois. The court has set a deadline for fact discovery to be completed by June 16, 2023, expert discovery to be completed by October 27, 2023, and a 5-day jury trial in April 2024.

Stay tuned to Big Molecule Watch for further developments in this case.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Kevin DeJong
Goodwin Procter LLP
Exchange Place
MA 02109
Tel: 6175701329
Fax: 6175231231
E-mail: JScalzi@goodwinlaw.com
URL: www.goodwinprocter.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about ASTRAZENECA PLC
07:25aASTRAZENECA : Jefferies reiterates its Neutral rating
03:45aASTRAZENECA : JP Morgan reiterates its Buy rating
07/06China allows AstraZeneca's COVID preventive drug in southern city
07/06Weak sterling boosts FTSE 100 amid political, growth worries
07/06UK stocks rebound as investors weigh political uncertainty
07/06Astrazeneca inks $1.2bn deal with US biotech firm
07/05European Bourses Hammered by Recession Fears; Euro Falls to 20-Year Low
07/05GLOBAL MARKETS LIVE : J Sainsbury, Foxconn, JPMorgan, Comcast, Tesla...
07/05ASTRAZENECA : Buy rating from Deutsche Bank
07/05AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening ha..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 717 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 402 M - -
P/E ratio 2022 40,3x
Yield 2022 2,26%
Capitalization 203 B 203 B -
EV / Sales 2022 5,19x
EV / Sales 2023 4,77x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 130,69 $
Average target price 142,13 $
Spread / Average Target 8,76%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC26.41%202 500
JOHNSON & JOHNSON4.13%469 179
PFIZER, INC.-12.55%295 975
ROCHE HOLDING AG-14.71%272 233
ABBVIE INC.12.65%269 537